Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

被引:146
作者
Emens, LA
Jaffee, EM
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Immunol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Pathol, Baltimore, MD 21231 USA
[4] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Pharmacol, Baltimore, MD 21231 USA
关键词
D O I
10.1158/0008-5472.CAN-05-1797
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.
引用
收藏
页码:8059 / 8064
页数:6
相关论文
共 55 条
[21]  
GORELIK L, 1994, CANCER IMMUNOL IMMUN, V39, P117, DOI 10.1007/BF01525317
[22]   EXPRESSION OF THE NEU PROTOONCOGENE IN THE MAMMARY EPITHELIUM OF TRANSGENIC MICE INDUCES METASTATIC DISEASE [J].
GUY, CT ;
WEBSTER, MA ;
SCHALLER, M ;
PARSONS, TJ ;
CARDIFF, RD ;
MULLER, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10578-10582
[23]  
Hu HM, 2002, CANCER RES, V62, P3914
[24]   Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation [J].
Jaffee, EM ;
Hruban, RH ;
Biedrzycki, B ;
Laheru, D ;
Schepers, K ;
Sauter, PR ;
Goemann, M ;
Coleman, J ;
Grochow, L ;
Donehower, RC ;
Lillemoe, KD ;
O'Reilly, S ;
Abrams, RA ;
Pardoll, DM ;
Cameron, JL ;
Yeo, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :145-156
[25]   Down-regulation of HLA class I antigen-processing molecules in malignant melanoma - Association with disease progression [J].
Kageshita, T ;
Hirai, S ;
Ono, T ;
Hicklin, DJ ;
Ferrone, S .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (03) :745-754
[26]   Mouse toll-like receptor 4•MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol [J].
Kawasaki, K ;
Akashi, S ;
Shimazu, R ;
Yoshida, T ;
Miyake, K ;
Nishijima, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) :2251-2254
[27]  
Keane MM, 1999, CANCER RES, V59, P734
[28]   The roles of the new negative T cell costimulatory pathways in regulating autoimmunity [J].
Khoury, SJ ;
Sayegh, MH .
IMMUNITY, 2004, 20 (05) :529-538
[29]   neu antigen-negative variants can be generated after neu-specific antibody therapy in neu Transgenic mice [J].
Knutson, KL ;
Almand, B ;
Dang, YS ;
Disis, ML .
CANCER RESEARCH, 2004, 64 (03) :1146-1151
[30]  
LAHERU D, P AACR PANCR CANC 20